AbbVie stock climbs after Q3 results and raised full-year adjusted earnings guidance
FROM THE WIRE · FINANCE.YAHOO.COM
AbbVie entered this Q3 2026 report with a reputation as a high multiple, high expectation pharma giant. The stock had already climbed roughly 21% over the past three months and then rose another 3.1% to about US$294.83 after the release. That price move reflects one headline…
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: expected bullishStrong quarterly results and a raised adjusted earnings guidance support the stock of a large pharma company.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01Net revenue in the third quarter was US$17.4 billion.
- 02Basic earnings per share were US$2.38 in the quarter.
- 03The stock rose 3.1% to about US$294.83 after the release.
NEWS IMPACT AND MARKET REACTIONChange since the story · reference
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets